Advertisement


Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives

2016 San Antonio Breast Cancer Symposium

Advertisement

Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.



Related Videos

Breast Cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).

Breast Cancer

Sonja Vliek, MD, and Sabine Linn, MD, PhD, on Early Breast Cancer: Results of the TEAM IIb Trial

Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).

Breast Cancer

Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial

Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).

Breast Cancer

Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial

Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).

Advertisement

Advertisement




Advertisement